Physician profile
Samuel Friedman
NPI 1366836611
$8,118.70
in general payments reported to CMS, 2019-2025
34 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $761 · 2021: $1,097 · 2022: $1,544 · 2023: $932 · 2024: $1,220 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,668.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,235.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,144.05 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $754.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $657.01 | 2022-2025 | |
| Pfizer INC. | $564.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $548.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Amgen INC. | $460.79 | 2019-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $459.12 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.69 | 2020-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $230.20 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $216.03 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $210.67 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $207.73 | 2021-2025 | |
| Amarin Pharma, INC. | $155.84 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $131.71 | 2021-2024 | Contrave |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.18 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $96.22 | 2020-2021 | |
| Bausch Health US, LLC | $93.15 | 2021-2025 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $81.63 | 2019-2022 | |
| Esperion Therapeutics, INC. | $81.44 | 2024-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.57 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $44.78 | 2022 | |
| Cranial Technologies, INC | $29.40 | 2022-2025 | Doc Band |
| Biohaven Pharmaceuticals, INC. | $28.61 | 2021 | |
| Astellas Pharma US INC | $26.77 | 2019 | |
| Ibsa Pharma INC. | $26.65 | 2021 | |
| Eisai INC. | $24.94 | 2019-2021 | |
| Abbott Laboratories | $18.93 | 2023 | Freestyle Libre 3 |
| Lundbeck LLC | $18.60 | 2024 | Rexulti |
| Mylan Specialty L.P. | $16.58 | 2022 | |
| Seqirus USA INC | $16.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.96 | 2023 | |
| Dermira, INC. | $15.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.